Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | MicrobiomeTrials← Back to trialsNCT05263050
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-01-21Est. Completion: 2026-12
Enrollment target: 111 participants Locations- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Other microbiome trials you might be interested in
Colorectal CancerPancreatic CancerMelanomaOvarian CancerGastric CancerEsophageal CancerHepatocellular CarcinomaRenal Cell CarcinomaBreast CancerSarcomaBladder CancerLung CancerProstate CancerCervical CancersHead and Neck CancersAdrenal Gland Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus t…
St Louis, United StatesEst. completion Jan 31, 2027
Metastatic CancerMelanoma CancerLung CancerBladder CancerRenal CancerHead/Neck Cancers
Drugs called checkpoint inhibitors help the immune system fight cancer. When the effectiveness of these drugs wears off,…
Hartford, United StatesEst. completion Oct 2027
Metastatic MelanomaAdvanced Locoregional MelanomaMetastatic Renal Cell CarcinomaClear Cell Histology
Background:
Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is use…
Bethesda, United StatesEst. completion Sep 1, 2031